Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Sponsor: BioAge Labs, Inc.
Summary
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.
Official title: A Phase 2, Randomized, Double-Blind, Dose-Range, Placebo-Controlled, 12-Week Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2026-06-11
Completion Date
2026-12
Last Updated
2026-06-18
Healthy Volunteers
No
Conditions
Interventions
Oral BGE-102
Capsules
Oral Placebo Matching BGE-102
Capsules
Locations (13)
Site 108
Chandler, Arizona, United States
Site 115
Peoria, Arizona, United States
Site 110
Tucson, Arizona, United States
Site 100
Rogers, Arkansas, United States
Site 109
Maitland, Florida, United States
Site 102
Miami, Florida, United States
Site 104
Port Orange, Florida, United States
Site 103
Lexington, Kentucky, United States
Site 106
Rockville, Maryland, United States
Site 113
Kansas City, Missouri, United States
Site 112
Austin, Texas, United States
Site 101
San Antonio, Texas, United States
Site 105
San Juan, Puerto Rico